Daewon Pharmaceutical대원제약
003220 · KOSPI · ₩003220 · 대원제약
₩7,700▼ ₩60 (0.77%)End-of-day · Oct 29, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 45.7% | 45.1% | 48.0% | 48.8% | 49.7% | 49.8% |
| Operating margin | −0.0% | 0.6% | 4.7% | 6.1% | 9.0% | 5.5% |
| Net margin | 0.4% | −0.2% | 2.4% | 4.5% | 6.7% | 2.0% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +1.5% | +1.2% | +13.5% | +10.0% | +35.2% | — |
| Operating income growth | −104.1% | −87.7% | −12.4% | −25.1% | +121.4% | — |
| Net income growth | +290.8% | −109.7% | −40.6% | −25.1% | +357.1% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 1.0% | −0.5% | 5.2% | 9.2% | 13.6% | 3.2% |
| Return on assets | 0.6% | −0.7% | 1.7% | 4.9% | 6.9% | 1.5% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 107.9% | 123.5% | 105.0% | 92.2% | 82.3% | 96.7% |
| Net debt to equity | 42.9% | 44.3% | 37.4% | 43.1% | 36.1% | 36.3% |
| Current ratio | 112.4% | 118.6% | 128.3% | 114.6% | 161.8% | 176.7% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Daewon Pharmaceutical / 대원제약 / 003220 / KRX:003220
Source: KRX statistical information